Myelodysplastic Syndrome (MDS)

Advanced Disease

- Matched Related Donor
  - BMT377: Phase Ib/III in Advanced Hematologic Malignancies Undergoing Allogeneic HCT with Either Orca-T, a T-Cell-Depleted Graft w/ Additional Infusion of Conventional T Cells & Regulatory T Cells, or SoC Allogeneic Graft
    - PI: Meyer
    - Sponsor: Orca Biosystems

- Matched Unrelated Donor
  - BMT343: Phase Ib T-Cell-Depleted Graft + Conventional & Regulatory T Cells in Advanced Hematologic Malignancies
    - PI: Meyer
    - Sponsor: Orca Biosystems

- Mismatched Unrelated
  - BMT338: Phase I DonorGrafts Derived From OrcaGraft w/GVHD Prophylaxis in MA-alloHCT in Hematologic Malignancies
    - PI: Meyer
    - Sponsor: Orca Biosystems

- Haplo
  - BMT391: Phase II HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide in Hematologic Malignancies
    - PI: Arai
    - Sponsor: National Marrow Donor Program (NMDP)

CR

- None at this Time
  - BMT372: Phase I Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
    - PI: Meyer
    - Sponsor: Stanford University

- BMT342: Phase II/III to Identify Novel Intervention to Aleviate Morbidity & Mortality After Allogeneic HCT
  - PI: Johnston
  - Sponsor: Fred Hutchinson